Stoke Therapeutics (STOK) and Its Rivals Head to Head Survey

Stoke Therapeutics (NASDAQ:STOK) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Stoke Therapeutics to similar businesses based on the strength of its institutional ownership, profitability, dividends, analyst recommendations, valuation, risk and earnings.

Insider and Institutional Ownership

47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Stoke Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1	0	10	0	2.82
Stoke Therapeutics Competitors	9792	15073	45355	1574	2.54

Stoke Therapeutics currently has a consensus price target of $44.17, suggesting a potential upside of 65.00%. As a group, “Biotechnology” companies have a potential upside of 96.40%. Given Stoke Therapeutics’ rivals higher possible upside, analysts clearly believe Stoke Therapeutics has less favorable growth aspects than its rivals.

Volatility & Risk

Stoke Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Stoke Therapeutics’ rivals have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.

Profitability

This table compares Stoke Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-862.07%	-66.76%	-58.10%
Stoke Therapeutics Competitors	-9,051.23%	-201.20%	-30.64%

Earnings & Valuation

This table compares Stoke Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Stoke Therapeutics	$28.21 million	-$6.89 million	-7.10
Stoke Therapeutics Competitors	$727.61 million	$12.25 million	-10.24

Stoke Therapeutics’ rivals have higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Stoke Therapeutics rivals beat Stoke Therapeutics on 7 of the 13 factors compared.

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.